Fundraising FoxThe Column Group — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.
BiotechDeep TechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)
Board seatPeter SvennilsonTim KutzkeyDavid V. Goeddel· per SEC Form D
Co-investorsBerkeley FrontierIaso VenturesViking GlobalYsios CapitalAlexandriaFidelity Investments+8 more
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechNew York, US
Jeff Goater(Executive Officer, Director)inKim Seth(CEO)in
BoardTim Kutzkey(Executive Officer, Director, Promoter)in
Co-investorsDCVC (Data Collective)AlexandriaDCVC BioLux Capital
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep TechSan Diego, US
Michael Martin, Ph.D.(Chief Executive Officer, President)Jorge F. DiMartinoinMichael Martin(President, Chief Executive Officer)inStephen Mullennix(Executive Officer)inSerge Messerlian, M.Sc., M.B.A.(Chief Executive Officer)
BoardSerge Messerlian(Director)in
Co-investorsaMoonCRV (Charles River Ventures)DCVC (Data Collective)M VenturesNeotribe VenturesPivotal Life Sciences+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.